Recent News

• 09.16.2025 - Lookalike Audiences That Work: Why AI Gives Agencies an Unfair Advantage
• 09.08.2025 - Pelthos Therapeutics to Participate in Upcoming September Investor Conferences
• 09.02.2025 - Pelthos Therapeutics to Participate in the 2025 Wells Fargo Healthcare Conference
• 08.18.2025 - Pelthos Therapeutics Reports Second Quarter 2025 Financial Results for Legacy Operations and Provides Business Update
• 07.10.2025 - Pelthos Therapeutics Launches ZELSUVMI™ (berdazimer) Topical Gel 10.3%, the First and Only FDA-Approved At-Home Treatment for Molluscum Contagiosum
• 07.09.2025 - VisitIQ Announces Corporate Rebrand and Capital Structure Clarity Amid Rapidly Accelerating Growth

Recent Filings

• 09.16.2025 - 8-K/A Current report
• 09.03.2025 - EX-99.1 EX-99.1
• 09.03.2025 - 8-K Current report
• 08.28.2025 - S-3 Registration statement under Securities Act of 1933
• 08.18.2025 - 8-K Current report
• 08.18.2025 - EX-99.1 EX-99.1
• 08.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.13.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 07.25.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 07.23.2025 - 4 Statement of changes in beneficial ownership of securities